A Study of Duvelisib in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL)

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2018
This is a multi-center, parallel cohort, open-label, Phase 2 study of duvelisib, an oral dual inhibitor of PI3K-δ,γ, in patients with relapsed/refractory Peripheral T-cell Lymphoma (PTCL).
Epistemonikos ID: a6c3b61e989db88fde88bb5b96df44af612016f6
First added on: May 21, 2024